Horizon Pharma plc buy tamam
Start price
07.08.15
/
50%
€29.31
Target price
21.07.16
€36.08
Performance (%)
-41.03%
End price
21.07.16
€17.28
Summary
This prediction ended on 21.07.16 with a price of €17.28. The BUY prediction by tamam for Horizon Pharma plc performed very badly with a performance of -41.03%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Horizon Pharma plc | - | - | - | - |
| iShares Core DAX® | -0,38 % | 1,09 % | 11,64 % | 60,42 % |
| iShares Nasdaq 100 | -0,41 % | -1,97 % | 7,27 % | 87,82 % |
| iShares Nikkei 225® | 1,84 % | 10,26 % | 31,38 % | 66,93 % |
| iShares S&P 500 | -0,71 % | 0,44 % | 4,30 % | 60,46 % |
Comments by tamam for this prediction
In the thread Horizon Pharma plc diskutieren
tamam stimmt dem Crowdsentiment von 'Buy' zu
Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.
(Laufzeit überschritten)
Stopped prediction by tamam for Horizon Pharma plc
Horizon Pharma plc
Start price
Target price
Perf. (%)
€24.60
26.08.19
26.08.19
€69.00
04.11.21
04.11.21
284.63%
05.11.21
05.11.21
